Myriad Genetics (MYGN) Stock Gets Fair Value Boost After Prenatal Sale And Q3 Update
Myriad Genetics (MYGN) has seen its fair value estimate increase from US$4.49 to US$5.90 per share following the sale of its prenatal business and a recent Q3 update. Analysts are recalibrating expectations, with price targets now ranging from US$5 to US$8, reflecting optimism about reduced financial risk and a more focused company, despite ongoing questions about growth and reimbursement. The sale of the prenatal business for US$210m to Labcorp is seen as a key de-risking event.
HCA Healthcare and Learning Undefeated Bring Mobile STEM Lab to Herndon High School
HCA Healthcare and Learning Undefeated partnered to bring a 1,000-square-foot Mobile Exploration Lab to Herndon High School, offering students hands-on experience in healthcare careers. Students engaged in an interactive activity mirroring real-world patient care, focusing on diabetes and glucose monitoring. The initiative aims to inspire the next generation of healthcare talent in Northern Virginia and showcase diverse career opportunities beyond traditional doctor and nurse roles.
DaVita Inc. (DVA) Stock forecasts
Argus has lowered its target price for DaVita Inc. (DVA) to $164.00, citing the company's position as the largest provider of dialysis services in the U.S. with about 35% market share. The current stock price for DVA is $156.34. The report was published on November 18, 2026.
Labcorp selected for biomarker testing in Florida prostate-cancer study
Labcorp has been selected by OTraces to perform biomarker testing for a Florida prostate-cancer study involving approximately 950 men, funded by a US$2 million state grant. The study aims to evaluate OTraces' platform's ability to predict biopsy outcomes better than standard PSA testing and distinguish aggressive from indolent disease. This partnership follows Labcorp's recent agreement to acquire 4Kscore, an existing prostate-cancer blood test, from OPKO Health, Inc.
Labcorp EVP Amy Summy sells $135,991 of common stock By Investing.com
Amy B. Summy, EVP and Chief Marketing Officer at Labcorp Holdings Inc. (LH), sold 365 shares of common stock for $135,991 on November 16, 2026. This sale occurred as Labcorp's stock neared its 52-week high, with InvestingPro analysis suggesting it is overvalued. The transaction follows a strong third-quarter performance for 2026, where Labcorp exceeded earnings and revenue expectations, leading Truist Securities to raise its price target.
Myriad Genetics expands SRL partnership in Japan to support future growth
Myriad Genetics has expanded its partnership with SRL, a leading clinical laboratory testing company in Japan, to enable local testing for its BRACAnalysis Diagnostic System. This collaboration aims to improve testing efficiency, shorten turnaround times for patients and clinicians by performing wet lab work locally, and establish a foundation for future precision medicine and companion diagnostic offerings in Japan. The move is expected to strengthen Myriad's position in its largest international market.
Labcorp and Grupo Fleury Collaborate to Boost Clinical Trial Operations in Brazil
Labcorp announced a partnership with Grupo Fleury to enhance clinical trial operations in Brazil, with local kit assembly scheduled for early 2027 and laboratory operations by late 2027. This collaboration aims to expand Labcorp's global clinical trial support network to five continents, improve efficiency, and reduce reliance on international shipping for sponsors. The initiative also seeks to broaden access to research opportunities and strengthen Brazil's clinical research ecosystem.
Labcorp expects local kit assembly to shorten kit delivery times in Brazil.
Labcorp announced a collaboration with Grupo Fleury to expand its clinical trial operations in Brazil. This expansion will include local clinical trial kit assembly starting in early 2027, followed by laboratory operations by the end of 2027. The initiative aims to reduce kit delivery times, lessen reliance on international shipping, and improve operational efficiency for trial sponsors in the region.
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
Insight Molecular Diagnostics Inc. (IMDx) reported its third-quarter 2026 results, highlighting progress with the FDA review of its GraftAssureDx test for kidney transplant rejection and the initiation of patient enrollment in its GALACTIC registry study. The company anticipates submitting its complete response to the FDA's request for additional information by January 21, 2027. IMDx posted Q3 2026 revenue of $559,000, with operating expenses decreasing due to winding down FDA submission costs, and is preparing for the commercial launch of GraftAssureDx.
VivoSim Labs Presents Landmark NAMkind™ Liver and Intestine Toxicology Studies at ACT Annual Meeting
VivoSim Labs announced it is presenting two significant studies at the 2026 American College of Toxicology Annual Meeting, showcasing its NAMkind™ Liver and Intestine platforms. These platforms use 3D human models to identify drug-induced liver injury and gastrointestinal toxicity more effectively than traditional animal tests, which often miss human-specific liabilities. The studies demonstrated the models' ability to flag toxicity in drug candidates that previously passed animal tests but failed in human trials, offering a valuable tool for biopharma developers to reduce costly clinical failures and optimize lead candidate selection.
Three customers account for all Q3 revenue as Scienture Holdings (SCNX) posts a wider loss.
Scienture Holdings (SCNX) reported a widened net loss of $6.01 million in Q3 2026, despite a significant increase in revenue to $1.25 million, primarily driven by sales of its new products, REZENOPY™ and ARBLI™. The company's revenue heavily relies on three wholesale distributors, which accounted for all Q3 revenue, highlighting customer concentration risk. While management believes existing cash and planned financing will sustain operations for at least 12 months, continued success depends on product adoption and securing additional capital.
Reflecting on testing & diagnostics services stocks’ Q3 earnings: Guardant Health
This article reviews the Q3 earnings of testing & diagnostics services stocks, focusing on Guardant Health (GH) which reported strong revenue growth and exceeded analyst expectations. It also highlights the performance of other companies in the sector, including NeoGenomics (NEO), Quest Diagnostics (DGX), Labcorp (LH), and RadNet (RDNT), detailing their revenue, growth, and market reactions. The sector as a whole experienced solid Q3 results with revenues beating consensus estimates.
Missed NeoGenomics' Rally? Here's What Buyers Saw
NeoGenomics' stock has seen a 54.9% return over the past year, prompting investors to consider what drove this rally. While a bullish narrative focused on aging populations and digital health tools driving oncology testing suggested a fair value of US$14, a bearish view highlighted margin pressures and regulatory risks. Recent Q3 2026 results showed improved revenue and narrowed losses, supporting the bullish thesis, though profitability remains unproven.
Can Labcorp Holdings (LH) Hold Its Value After The $375 Million Deal?
Labcorp Holdings has seen an 80.6% share price return over the past three years, with a recent US$375 million acquisition of Millennium Health adding to its toxicology testing capabilities. The company currently trades at a P/E ratio of 30.0x, higher than the healthcare sector average, which analysts believe is consistent with its growth drivers and risk profile. Despite a strong market performance, recent insider share sales raise questions about management's actions regarding their holdings.
What Is Drawing Fresh Attention To OPKO Health (OPK)?
OPKO Health (OPK) has gained attention after reporting third-quarter earnings and new 2026 revenue guidance, leading to recent share price gains. While Simply Wall St's analyst consensus suggests the stock is 60% undervalued with a fair value of $4.15 per share, another view indicates it looks expensive based on its Price/Sales ratio compared to the healthcare sector and peers. The company's future relies on improving loss-making operations and successful partnered programs, with a recent sale of clinical diagnostics businesses expected to free up capital for higher-margin pharmaceutical programs.
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms
Labcorp reported strong third-quarter growth driven by its central laboratory business and diagnostic testing, with revenue up 7% and adjusted EPS increasing 14.5%. Despite raising its guidance, the company is preparing for a potential $125 million reduction in government reimbursement rates in 2027 due to changes under the Protecting Access to Medicare Act (PAMA). Labcorp plans to mitigate this risk through growth initiatives, acquisitions, and increasing its LaunchPad savings target.
Exagen Inc. (NASDAQ:XGN) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Exagen Inc. (NASDAQ:XGN) shares recently plunged 42% following its latest quarterly results, with revenues meeting expectations at US$18m but statutory losses widening to US$0.25 per share. Analysts are forecasting US$80.8m in revenues for 2027, a 12% improvement, and a substantial 26% reduction in losses to US$0.56 per share. Despite these updates, the consensus price target of US$10.29 remains unchanged, indicating that analysts believe the business is performing in line with expectations, albeit with higher forecast losses.
After $1M in year-earlier revenue, Freenome (FRNM) posts a profit on license revenue.
Freenome (FRNM) reported a significant increase in Q3 2026 revenue to $183.5 million, up from $1.0 million in the year-ago quarter, driven primarily by a $182.5 million license agreement with Exact Sciences following FDA approval of its SimpleScreen CRC test. This led to a net income of $60.1 million, a substantial improvement from a $64.5 million net loss previously. The company also launched SimpleScreen Lung, a laboratory-developed lung cancer screening test, and secured $295.5 million in net proceeds from a July business combination and PIPE financing.
bioAffinity Technologies Advances CyPath Lung for Lung Cancer Survivor Surveillance
bioAffinity Technologies is exploring the use of its CyPath Lung test to monitor lung cancer patients who have completed curative-intent treatment, aiming to detect recurrence earlier. The noninvasive test, which uses flow cytometry and AI to identify malignant cells in sputum, can complement imaging by providing additional information on pulmonary nodules, helping physicians determine the need for further investigation versus continued surveillance. This initiative builds on CyPath Lung's proven ability to detect early-stage lung cancer and could significantly improve patient outcomes by enabling earlier intervention.
Labcorp Holdings stock hits all-time high at 374.4 USD
Labcorp Holdings Inc. (LH) stock has reached an all-time high of $374.4 USD, surpassing its 52-week high and surging 49.47% year-to-date. This milestone follows stronger-than-expected Q3 2026 results, with adjusted earnings and revenue exceeding forecasts. Analysts at Truist Securities have raised their price target for Labcorp to $395, maintaining a Buy rating.
Labcorp (NYSE:LH) EVP Brian Caveney Sells 2,000 Shares of Company Stock
Labcorp EVP Brian Caveney sold 2,000 shares of company stock for $744,080 on November 10th, reducing his total holdings to 34,562 shares. This transaction follows Labcorp's strong quarterly earnings report, where it surpassed EPS estimates and saw a 6.9% year-over-year revenue increase. The company also declared a quarterly dividend of $0.72 per share, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $369.08.
Labcorp EVP, Pres of BLS, CMO & CSO Sold Shares Worth Over $744K
Brian J. Caveney, an executive at Labcorp Holdings, sold 2,000 shares of the company stock at $372.0401 per share, totaling $744,080. Following this transaction, Caveney directly holds 34,562 shares. This insider transaction was disclosed via an SEC Form 4 filing.
After selling 2,000 shares, Labcorp (LH) executive Caveney holds 34,562 directly.
Labcorp Holdings Inc. (LH) executive Brian J. Caveney sold 2,000 shares of common stock at $372.0401 per share on November 10, 2026. Following this transaction, Caveney directly holds 34,562 shares. The reported post-sale balance includes shares acquired through the company's 2025 Employee Stock Purchase Plan.
23 Mid Cap Stocks Hit 52-Week Highs On Wednesday
On Wednesday, November 11, 23 Mid Cap US and Canada-listed stocks within the Trefis coverage universe reached 52-week highs. Mid Cap is defined as a market value between $10 billion and $40 billion, with Cboe Global Markets (CBOE) being the largest at $38.6 billion. The Financials sector accounted for 8 of these 23 companies, while the S&P 500 was down 2.3% over the past month.
QuidelOrtho launches VITROS 450 waterless chemistry testing for low-volume laboratories
QuidelOrtho Corporation has launched the VITROS 450 Chemistry System in key global markets, offering a compact, waterless analyzer for low-volume and community-based laboratories. This system utilizes MicroSlide™ technology to provide high-quality, reliable chemistry testing, particularly benefiting settings with limited water, space, or staffing. The launch aims to advance diagnostic access and quality across diverse healthcare environments by offering a sustainable and user-friendly solution.
$1.77B in Q3 revenue at Waters (WAT) came with a drop in profit.
Waters Corporation (WAT) reported a significant increase in Q3 2026 revenue to $1.77 billion, up from $800 million in the prior-year quarter, primarily driven by the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions (BDS) business. However, net income for the quarter fell to $81 million from $149 million, and for the first nine months, the company reported a net loss of $127 million compared to a net income of $417 million a year earlier. The decline in profit was largely due to acquisition-related costs, including purchased intangibles amortization, inventory and fixed asset step-up expenses, and restructuring charges from a workforce reduction.
Learn Why The Bull Case For Guardant Health Stock Could Change Following Revenue Guidance Raise
Guardant Health (NasdaqGS:GH) reported Q3 2026 sales of US$360.98 million and raised its full-year 2026 revenue guidance to US$1.36 to US$1.37 billion due to strong demand for its cancer screening and oncology tests. While this revenue growth supports the bullish narrative, the company continues to report significant net losses, keeping focus on cash burn and the path to profitability. Analyst models project rapid revenue expansion and a sharp swing to profitability over the next few years, but also factor in dilution and a rich valuation.
RadNet Q3 2026 Earnings Call Transcript
RadNet, Inc. reported record third-quarter revenue of $683 million, a 22.1% increase year-over-year, and adjusted EBITDA of $105 million, a 23.8% increase, driven by demand in advanced imaging, new centers, and joint ventures. The company announced the acquisition of ONRAD, forming a new Radiology Professional Services segment, expected to add significant revenue and EBITDA. RadNet also raised its 2026 full-year guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow due to strong performance and digital health growth.
A 36% narrower Q3 loss at Quanterix (QTRX) comes alongside a revenue decline.
Quanterix (QTRX) reported a 13% decline in Q3 2026 revenue to $35 million year-over-year, largely due to weaker instrument demand and reduced Accelerator Laboratory services. However, the company narrowed its net loss by 36% to $21.6 million compared to the previous year, with nine-month revenue rising to $104.3 million. Despite a challenging capital funding environment affecting instrument sales, the company is implementing strategic changes, including a reorganized commercial structure and increased focus on Alzheimer's diagnostics, to accelerate revenue growth.
161,429 Labcorp Holdings Inc. $LH Shares Sold by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 7.2% in the third quarter, selling 161,429 shares and leaving it with 2,075,528 shares valued at $632.21 million. Other institutional investors also adjusted their holdings, with several brokerages maintaining "Buy" or "Hold" ratings and an average price target of $369.08. Labcorp recently reported strong quarterly earnings, declared a dividend, and experienced insider selling by executives.
FY2026 EPS Estimates for OPKO Health Raised by HC Wainwright
HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.18 per share from a previous projection of a $0.23 loss, while maintaining a "Buy" rating. The biotechnology company recently reported a quarterly loss of $0.07 per share, meeting analyst consensus, though its revenue of $130.83 million missed estimates and represented a 56.9% year-over-year decline. This adjustment follows OPKO's agreement to sell most of its remaining BioReference diagnostic operations to Labcorp for $722 million.
Why Labcorp Holdings (LH) Is Back In The Spotlight
Labcorp Holdings (LH) has re-entered the investor spotlight following its Q3 2026 results and an increased full-year revenue growth outlook, leading to strong share price performance. The stock is currently debated between being 3% overvalued based on common fair value estimates and heavily undervalued according to a Discounted Cash Flow (DCF) model. Investors are evaluating the growth in specialty testing against potential risks like PAMA cuts and the divergence in valuation metrics.
Form 144 LABCORP HOLDINGS INC. For: 8 November By Investing.com
This article announces the filing of Form 144 for Labcorp Holdings Inc. on November 8, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider transactions or sales by affiliates. The report was published by Investing.com, a financial news platform.
NeoGenomics (NEO) Cut Its Losses In Q3, Is The 26% Undervaluation Case Convincing?
NeoGenomics (NEO) reported higher Q3 2026 sales of US$209.25 million and a significantly reduced net loss of US$7.55 million. The stock is currently trading at US$16.84, with a popular narrative suggesting it is 26% undervalued at a fair value of US$22.89, driven by expected operating efficiencies and growth. However, another perspective suggests the stock looks pricey based on a sales multiple (P/S of 2.8x) compared to industry and peer averages, indicating potential multiple risk if sentiment cools.
What Labcorp Holdings Shares Earnings Beat Means For Shareholders
Labcorp Holdings reported a strong third quarter and nine months for 2026, with sales of US$3,810 million and net income of US$262.8 million for the quarter, and an increased full-year revenue growth guidance to 5.9% to 6.7%. This positive outlook is driven by testing demand, productivity efforts, and a robust biopharma services pipeline, despite ongoing concerns about potential PAMA impacts. The company's performance and guidance reinforce its investment narrative centered on steady test volumes, specialty diagnostics, and long-duration biopharma contracts.
PacBio (PACB) Q3 2026 Earnings Call: SPRQ-Nx-Einführung und eingeengte Umsatzprognose
PacBio reported a 6% increase in Q3 2026 revenue to $40.6 million, driven by strong instrument sales and growth in EMEA, despite a dip in gross profit due to higher memory costs. The company narrowed its full-year revenue forecast to $155-$160 million and reduced operating expense expectations through restructuring. PacBio remains committed to its SPRQ-Nx rollout and aims for cash flow breakeven by 2028.
Q3 revenue slips to $202.7M as Myriad Genetics (MYGN) posts a wider net loss.
Myriad Genetics reported a Q3 2026 revenue of $202.7 million, a slight decrease from $205.7 million a year earlier, and a widened net loss of $43.9 million, compared to $27.4 million in Q3 2025. The company announced an agreement to sell its Prenatal Health business to Laboratory Corporation of America for $210 million in cash, aiming to use the proceeds for general corporate purposes, including debt repayment and investment in its Cancer Care Continuum business. For the first nine months of 2026, revenue was $593.8 million, with a net loss of $121.2 million.
21,926 Shares in Labcorp Holdings Inc. $LH Purchased by Mirae Asset Global Investments Co. Ltd.
Mirae Asset Global Investments Co. Ltd. recently acquired 21,926 shares of Labcorp Holdings Inc. (NYSE:LH) during the third quarter, a stake valued at approximately $6.76 million. This acquisition comes as Labcorp reported strong quarterly earnings, beating analyst estimates with $4.78 adjusted EPS and a 6.9% year-over-year revenue increase. The company has also seen positive analyst sentiment, with several firms raising price targets and ratings, contributing to a consensus "Moderate Buy" rating for the stock.
Natera Inc (NTRA) Q3 2026 Earnings Call Highlights: Revenue Jumps 34% as Guidance Raised Above ...
Natera Inc. reported strong Q3 2026 results with revenue jumping 34% year-over-year to $794 million and processing a record 1.1 million tests. The company raised its full-year 2026 revenue guidance to over $3 billion and set an ambitious long-term goal to double revenues to $6 billion by 2029. Despite increased operating expenses for R&D and early cancer detection, management expressed confidence in achieving its targets through core oncology growth, global expansion, and pharma partnerships.
How Investors May Respond To AMN Healthcare Services Stock After Profit Turnaround
AMN Healthcare Services reported a significant profit turnaround in the third quarter and first nine months of 2026, with net income reaching US$116.72 million year-to-date. This shift is crucial for its investment narrative, suggesting that sustained profitability from flexible staffing and permanent hires in hospitals could offset pressures in other segments. While the profit rebound provides financial flexibility for tech investments, concerns regarding high debt, one-off items, and softer demand in specific solutions persist, framing future execution challenges for the company.
OPKO Health (NASDAQ:OPK) Director John Paganelli Sells 9,175 Shares of Company Stock
OPKO Health Director John Paganelli sold 9,175 shares of company stock at an average price of $1.82, totaling approximately $16,698.50. This sale reduced his direct ownership by 2.30%, leaving him with 389,914 shares. The company recently reported a quarterly loss matching analyst estimates but missed revenue expectations, and is selling most of its BioReference diagnostic operations to Labcorp for $722 million to focus on biotech.
Missed NeoGenomics' Rally? Here Is What Holders Saw
NeoGenomics (NasdaqCM:NEO) saw a 64.4% return for investors over the past year, driven by strong Q3 2026 results, new Medicare coverage for RaDaR ST, and an FDA-approved PTEN diagnostic. The company's revenue increased from US$187.8m to US$209.3m, and its net loss narrowed, supporting a bullish outlook on higher-value oncology assays and improved efficiency. While profitability remains negative, the market's current valuation of US$17.15 reflects a belief in the company's ability to scale new offerings and achieve higher margins through strategic investments.
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
Pacific Biosciences (PACB) reported 6% revenue growth in Q3 2026, reaching $40.6 million, driven by the adoption of its SPRQ-Nx sequencing chemistry and increased instrument sales. Despite a decline in consumables revenue and academic funding constraints, the company is expanding its clinical and AI programs, with clinical business now exceeding 20% of its total revenue. PacBio narrowed its full-year revenue outlook to $155 million-$160 million and expects to achieve cash flow breakeven in 2028.
Labcorp raised to Buy at HSBC on M&A and diagnostics momentum
HSBC has upgraded Labcorp Holdings (LH) to Buy from Hold and increased its price target to $410 from $330 per share, citing the company's M&A strategy and strong momentum in its diagnostics business. Analyst Yessica Sanchez believes that Labcorp's valuation, despite being higher than its historical average, is still at a discount to Quest Diagnostics (DGX) and justifies further re-rating due to growth, specialty testing mix, and M&A execution. Potential headwinds include integration complexities and changes to the Protecting Access to Medicare Act, which could reduce reimbursement rates.
US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
US hospital operators are anticipating significant revenue pressure in 2027 due to the expiration of Affordable Care Act subsidies, leading to over 3 million people losing insurance coverage. Additionally, Medicaid supplemental payments are set to decline sharply, and new work requirements for certain Medicaid adults, along with deeper reimbursement cuts starting in 2028, will further strain hospital finances. Major chains like HCA Healthcare, Tenet Healthcare, and Universal Health Services are already seeing increased self-pay patients and project substantial income reductions.
Labcorp evp Bryan Vaughn sells $108,232 in shares
Bryan T. Vaughn, Executive Vice President at Labcorp Holdings Inc., sold 306 shares of company stock for a total of $108,232. This transaction was conducted via a Rule 10b5-1 trading plan. The sale occurs as Labcorp shares trade near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued despite recent strong Q3 2026 performance and a raised price target from Truist Securities.
Labcorp evp Bryan Vaughn sells $108,232 in shares By Investing.com
Bryan T. Vaughn, EVP and President of Diagnostics at Labcorp Holdings Inc. (NASDAQ:LH), sold 306 shares of company stock for $108,232 on November 3, 2026, through a Rule 10b5-1 trading plan. This sale occurred while Labcorp shares were trading near their 52-week high, with the company demonstrating strong year-to-date returns and recent robust Q3 2026 financial performance that exceeded analyst expectations. Truist Securities subsequently raised its price target for Labcorp to $395, maintaining a Buy rating.
Form 4 Labcorp Holdings Inc: Bryan T. Vaughn (EVP and President, Diagnostics) For: 3 November
This article reports on a Form 4 filing for Labcorp Holdings Inc., detailing an insider transaction by Bryan T. Vaughn, EVP and President of Diagnostics, which occurred on November 3. The filing indicates a transaction involving Labcorp Holdings Inc. stock (LH), which saw a 0.90% increase.
Labcorp evp Bryan Vaughn sells $108,232 in shares By Investing.com
Bryan T. Vaughn, EVP and President of Diagnostics at Labcorp Holdings Inc. (NASDAQ:LH), sold 306 shares totaling $108,232 on November 3, 2026, through a Rule 10b5-1 trading plan. This insider sale occurs as Labcorp shares are trading near their 52-week high and are considered overvalued by InvestingPro. The company recently reported strong Q3 2026 results, exceeding analyst expectations and raising its full-year guidance, leading Truist Securities to increase its price target to $395.
Labcorp (NYSE:LH) Stock Moved Up to "Buy" by HSBC
HSBC upgraded Labcorp (NYSE:LH) stock from a "hold" rating to a "buy" rating, setting a price target of $410.00, which implies an 11.4% upside. This upgrade comes as Labcorp reported strong quarterly earnings, beating analyst estimates with an EPS of $4.78 and revenue of $3.81 billion, a 6.9% increase year-over-year. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $369.08.